We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety, Tolerability, and Efficacy of Deferasirox in MDS

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00469560
First Posted: May 4, 2007
Last Update Posted: November 22, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Gruppo Italiano Malattie EMatologiche dell'Adulto
  Purpose

Open label, single arm study on Deferasirox treatment in MDS patients with chronic transfusional hemosiderosis.

Patients receive daily oral dosis of Deferasirox in order to eliminate the quantity of iron administered during transfusions and, if needed, to reduce the overload of already present iron.

After an screening phase in which patients are evaluated according to eligibility criteria, a one year treatment phase foresees monthly visits to evaluate safety and efficacy signs.


Condition Intervention Phase
Myelodysplastic Syndromes Hemosiderosis Drug: Deferasirox Phase 3

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open Label, Multicenter Study to Evaluate Safety/Tolerability and Efficacy of Deferasirox (ICL670) in Myelodysplastic Syndrome Patients With Chronic Transfusional Hemosiderosis.

Resource links provided by NLM:


Further study details as provided by Gruppo Italiano Malattie EMatologiche dell'Adulto:

Primary Outcome Measures:
  • To evaluate the tolerability and safety profile of Deferasirox in pts with MDS with post-transfusional hemosiderosis [ Time Frame: On a monthly basis thereafter from baseline assessment. ]

Secondary Outcome Measures:
  • To evaluate Deferasirox efficacy as chelation therapy in terms of reduction of serum ferritin levels compared to basal levels [ Time Frame: At 3, 6, 9, and 12 months from baseline assessment. ]
  • To evaluate the impact Deferasirox iron chelating therapy vs the normal demand of transfusions in a subgroup of pts that will not receive growth factors or chemotherapy according to their basal characteristics. [ Time Frame: On a monthly basis thereafter from baseline assessment. ]
  • Quality of Life evaluation. [ Time Frame: At 3, 6, 9, and 12 months from baseline assessment. ]
  • Compliance to chelating therapy evaluation. [ Time Frame: On a monthly basis thereafter from baseline assessment. ]

Enrollment: 158
Study Start Date: June 2007
Study Completion Date: November 2013
Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Deferasirox Drug: Deferasirox

Detailed Description:

It has been widely shown that an appropriate chelating therapy in chronic anemias transfusion dependent can prevent the overstock of iron and can reduce the already existing overstock reducing, then, the co-morbidity and improving survival.

In particular, some authors have shown in MDS affected patients undergoing intensive chelating therapy with deferoxamine haematological recovery with a reduction of the need of transfusions.

With the present study, we plan to evaluate the safety and efficacy of a therapy with the new oral chelating Deferasirox in MDS patients with transfusional hemosiderosis.

This is an open label, single arm study on Deferasirox treatment in MDS patients with chronic transfusional hemosiderosis.

Patients will receive daily oral dosis of Deferasirox in order to eliminate the quantity of iron administered during transfusions and, if needed, to reduce the overload of already present iron.

After an screening phase in which patients are evaluated according to eligibility criteria, a one year treatment phase foresees monthly visits to evaluate safety and efficacy signs.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients, both males and females, with low and intermediate I risk (IPSS score) Myelodysplastic syndrome and transfusion-induced hemosiderosis.
  • Age >=18 years
  • Patients who never received chelation therapy or who received a therapy with Desferal after a day of wash out
  • Medical history of at least 20 blood transfusions (equivalent to 100 ml/kg of red cells concentrate).
  • Availability of data concerning blood transfusions during the 12 weeks before screening
  • Serum ferritin >= 1000 µg/L at least twice (at least 2 week interval between the 2 analysis) during the year before the screening
  • Life expectancy > 12 months
  • Availability of at least 3 complete blood counts (before transfusions) during the 12 weeks before the screening

Exclusion Criteria:

  • Diagnosis different from MDS (i.e. myelofibrosis)
  • Severe renal impairment (creatinine clearance < 60 ml/min)
  • ALT/AST > 500 U/L
  • Active B and/or C hepatitis
  • Patients treated during the past 4 weeks with experimental drugs for MDS (including thalidomide, azacitidine, arsenic trioxide). These patients become eligible after a "wash out" of at least 4 weeks
  • Concomitant treatment with another iron-chelating agent
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00469560


Locations
Italy
SOC EMATOLOGIA ASO SS Antonio e Biagio
Alessandria, Italy
Ist.Ematologia e Oncologia Medica L.e A. Seragnoli
Bologna, Italy
CTMO-Ematologia Ospedale Binaghi
Cagliari, Italy
Ospedale "A. Businco"
Cagliari, Italy
Oncoematologia "A.O.R.N. S'Anna e S.Sebastiano"
Caserta, Italy
US Dipartimentale Centro per le Malattie del Sangue
Castelfranco Veneto, Italy
Università di Catania - Cattedra di Ematologia - Ospedale "Ferrarotto"
Catania, Italy
Policlinico di Careggi, Università delgi studi di Firenze
Firenze, Italy
Clinica Ematologica - Università degli Studi
Genova, Italy
Divisione di Ematologia e TMO - Ospedale "A. Cardarelli "- Azienda Ospedaliera di Rilievo Nazionale "A. Cardarelli"
Napoli, Italy
Clinica Ematol Università di Perugia, Policlinico Monteluce
Perugia, Italy
Ematologia- Università degli Studi "La Sapienza"
Roma, Italy
Università Cattolica del Sacro Cuore
Roma, Italy
Università degli Studi di Tor Vergata
Roma, Italy
Istituto di Ematologia - IRCCS Ospedale Casa Sollievo della Sofferenza
San Giovanni Rotondo, Italy
U.O. Ematologia, Azienda Ospedaliera Universitaria Senese
Siena, Italy
Ospedale Civile SS. Giovanni e Paolo
Venezia, Italy
Sponsors and Collaborators
Gruppo Italiano Malattie EMatologiche dell'Adulto
Investigators
Principal Investigator: Emanuele ANGELUCCI, Pr. Ospedale "A. Businco", Cagliari
  More Information

Publications:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Gruppo Italiano Malattie EMatologiche dell'Adulto
ClinicalTrials.gov Identifier: NCT00469560     History of Changes
Other Study ID Numbers: MDS0306
First Submitted: May 3, 2007
First Posted: May 4, 2007
Last Update Posted: November 22, 2016
Last Verified: November 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Gruppo Italiano Malattie EMatologiche dell'Adulto:
MDS
Chronic transfusional hemosiderosis
Deferasirox

Additional relevant MeSH terms:
Syndrome
Myelodysplastic Syndromes
Preleukemia
Hemosiderosis
Disease
Pathologic Processes
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Neoplasms
Iron Overload
Iron Metabolism Disorders
Metabolic Diseases
Deferasirox
Iron Chelating Agents
Chelating Agents
Sequestering Agents
Molecular Mechanisms of Pharmacological Action